A previous report demonstrated that endothelial cells have erythropoletin receptors and respond to this hormone with enha proliferation. The present study demostrates the existence of mRNA for erythropoletin receptor in human umbilica vein endothelial cells. We have reverse transcribed mRNA of endothellal cells and then used different PCR primers to amplify erythropoietin receptor target cDNA be-
tween exons 5 and 6 as well as 3-5 in addition to an internal standard DNA frgment. Correspondence of size as well as location of restriction endoudas sion (Ava H) was used in comparing the amplied faents ofhuman endothellal cell erythropoletin receptor to those oftwo human erythroleukemia cell lines, OCIM1 and K562. No a-or -globin mRNA was detected in endothellal cells but was readily demonstrable in OCIM1 cells. In addition, to determine whether the expression of human erythropoletin receptor on endothelial cells occurs in WVi, sections of umbi cord and placenta were immunosained with antibodies against the extracellular portion of the receptor; the results showed strong positive stining of the vascular endothelium.
Erythropoietin (Epo) is a 30,400-Da polypeptide known to be the principal hormone regulating the proliferation, differentiation, and survival of erythroid cells (1) . Its cell surface receptors, which belong to the hematopoietic (cytokine) receptor superfamily (2) , are considered highly specific for cells of the erythroid lineage. We have previously reported a proliferative effect of recombinant human erythropoietin (rhEpo) on cultured human umbilical vein endothelial cells (HUVECs) and bovine adrenal capillary endothelial cells (3) and Carlini et al. (4) have described a similar mitogenic effect on bovine pulmonary artery endothelial cells. In this study we used PCR techniques to detect and quantitate human Epo receptor (hEpoR) gene transcripts in HUVECs and compared the abundance ofthis mRNA with that expressed in the erythroleukemia cell lines OCIM1 and K562. K562 cells express only 4-6 hEpoRs per cell on average (5) , whereas OCIM1 cells exhibit about 3000 ofthese receptors per cell (6) .
As a negative control we used HeLa cells, which do not express hEpoR. In addition, we utilized a monoclonal antibody to the extracytoplasmic portion of hEpoR (37) which has recently become available to immunostain the endothelial lining of human blood vessels and demonstrated strong reactivity of the vascular endothelium.
MATERIALS AND METHODS HUVEC. HUVECs were obtained from umbilical cords from cesarean sections. The cells were cultured by standard methods in the presence of heparin and endothelial-cell growth supplement (7) . They were characterized by their homogeneous and typical cobblestone morphology, factor VIII antigen positivity, and the presence of Weibel-Palade bodies on electron microscopy. HUVECs were used for these studies after three to five passages.
For clonal culture to exclude contamination with hematopoietic stem cells, HUVECs (1-5 x 105 cells per ml) were plated in methylcellulose cultures as described (8), with the modification that half of the fetal bovine serum was replaced with human umbilical cord blood serum. Hematopoietic growth factors were added as follows: rhEpo, 2 units/ml; stem-cell factor, 10 pg/ml; granulocyte/macrophage-colonystimulating factor, 200 units/ml; interleukin 3, 200 units/ml; endothelial-cell growth factor, 20 ktg/ml. Preparation of mRNA. After 1-5 x 107 cells were harvested and washed twice with phosphate-buffered saline, RNA was extracted with guanidinium thiocyanate and lauryl sarcosinate (9) . mRNA was adsorbed onto oligo(dT)-cellulose columns (Pharmacia) and, after the columns were washed with highand low-salt solutions, was eluted with 10 mM Tris'HCl buffer containing 1 mM EDTA (pH 7.4) at 650C. Total amount and concentration of mRNA were determined spectrophotometrically and confirmed by agarose gel electrophoresis.
Reverse Transcription of RNA and Amplficaon of cDNA. An aliquot of mRNA (0.5-1 pg) was used for reverse transcription according to Gubler and Hoffmann (10) . Synthesis of the first-strand cDNA began at the 3' end of poly(A)+ mRNA by using (dT)5 primer in 20 1A of 50 mM Tris-HCl, pH 8.5/8 mM MgC12/30 mM KCl/0.01 mM dithiothreitol containing 8 units of RNase inhibitor (Boehringer Mannheim), 1 pM each dNTP, and 40 units of avian myeloblastoma virus reverse transcriptase (Boehringer Mannheim). The reaction was carried out at 420C for 60 min in a DNA thermal cycler (Perkin-Elmer). After the reaction was stopped, 5-10 p1 of sample was used for PCR amplification. Synthetic oligonucleotide primers from exon 5 (sense, 5'-GCA-CCG-AGT-GTG-TGC-TGA-CGA-A-3') and exon 6 (antisense, 5'-GGT-CAG-CAG-CAC-CAG-CAT-GAC-3') were used to amplify hEpoR target cDNA, giving rise to a 197-bp fragment (38) .
Results from endothelial cells were compared with results from OCIM1 cells (positive control) and HeLa cells (negative control). To determine the specificity of the reaction, the product of the PCR amplification was subjected to digestion with the restriction endonuclease Ava II to obtain the expected 57-bp and 140-bp fragments.
Quantitative PCR. To quantify hEpoR mRNA, mRNA was reverse transcribed (see above) and multiple reaction mix- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
an internal standard were added to each reaction mixture and coamplified (11) . The internal standard was constructed by PCR of hEpoR cDNA using the primer set 5'-GCGTCCCT-CTAGAGTTCGCGCT-3' and 5'-TGGCTCATCCGCTAGG-CGTCAG-3' and includes a 378-bp fragment extending from exon 3 to exon 5 of hEpoR (35) . PCR amplification using Taq DNA polymerase Stoffel fragment (Perkin-Elmer) was performed in 10 mM Tris-HCl, pH 8.3/10 mM KCl/3 mM MgCl2/0.2 mM dNTPs; 0.25-0.5 gg of mRNA was used for each PCR. Standard DNA and hEpoR primers were used at concentrations varying from 20 to 50 ng for HUVEC and OCIM1 mRNA. [a-32P]dCTP (2.5-3.0 pCi; 1 uCi = 37 kBq) was added. The thermal cycler program was begun with a melting step, 3 min at 940C, followed by 30-35 cycles of 940C for 1 min, 550C for 2 min, and 720C for 3 min. Final extension was at 72°C for 7 min. Products of the reaction were analyzed by electrophoresis in 2-2.4% agarose gels (SeaKem ME/ NuSieve GTG, 1:2; FMC). The bands representing hEpoR and the standard fragment were cut out for scintillation counting. hEpoR was quantified based on the amount of standard added and on radioactivity ofthe standard and ofthe hEpoR cDNA-specific band.
Immunohistochemistry. Representative sections from fresh human placentas and umbilical cords were fixed for 6-18 hr in 96% absolute ethanol/1% glacial acetic acid/3% distilled water. The tissue was processed manually and embedded in paraffin. Sections of 5 ,um were cut, heated at 55°C for 1 hr, deparaffinized in Clear-Rite-3 (Richard Allen, Richland, MI), and rehydrated in graded ethanol solutions to water. Endogenous peroxidase activity was quenched by freshly prepared 3% hydrogen peroxide for 30 min, and the slides were rinsed and placed in phosphate-buffered saline (pH 7.3). Monoclonal anti-human erythropoietin receptor antibody (mh2er/ 16.5.1, mouse IgGl, affinity purified on protein A) (Genetics Institute, Cambridge, MA) was added at a dilution of 1:25 and incubated for 75 min. Biotinylated anti-mouse IgG was used as secondary antibody and was recognized by streptavidinperoxidase (labeled streptavidin-biotin kit, K-681; Dako); peroxidase activity was analyzed with 3-amino-9-ethylcarbazole (Vector Laboratories) as chromogen. The sections were counterstained with Harris hematoxylin. Similar tissue sections were stained for von Willebrand factor (vWF) with the standard Dako kit.
RESULTS AND DISCUSSION
Since umbilical cord blood is rich in hematopoietic stem cells, we took several safeguards to assure that the target cells were indeed endothelial cells and not a small number of contaminating hematopoietic progenitor cells. We extensively washed the umbilical cords free of contaminating blood, removed repeatedly all nonadherent cells, and saw no evidence of emperipolesis. More than 95% of the cells were positive for vWF. To avoid ingrowth of fibroblasts, we used HUVECs only at passages 3-5 from individual donors. We observed no proliferative effect of rhEpo on umbilical cord-derived fibroblasts or smooth muscle cells. Bovine adrenal capillary endothelial cells respond to rhEpo similarly to HUVECs even after 11-18 passages (3) . HUVECs plated in a methylcellulose stem-cell culture system in the presence of endothelial-cell growth factor produced a homogeneous endothelial layer with typical cobblestone morphology. Addition of hematopoietic growth factors failed to give rise to any hematopoietic colonies over a period of 1-4 weeks but did stimulate "capillary tube" formation as described in other angiogenic assays.
To demonstrate the presence of hEpoR mRNA in HUVECs, RNA PCR was performed with avian myeloblastosis virus reverse transcriptase and (dT)15 primer. Secondstrand cDNA synthesis and amplification of cDNA were performed with primers from exon S (sense) and exon 6 (antisense) of hEpoR mRNA (Fig. 1 ). The amplified fragment was subjected to digestion with Ava II, which splits the 197-bp target into 140-and 57-bp fragments. HUVECs yielded the expected fragment sizes, which were identical to those of OCIM1 cells, confirmation that the amplification product represented hEpoR mRNA. mRNA extracted from HeLacells did not exhibit any amplification product in the 197-to 57-bp range (Fig. 1A) . Amplification of a different target cDNA of HUVECs corresponding to a 265-bp fragment extending from exon 1 to exon 3 of hEpoR mRNA showed results identical to those obtained with OCIM1, as well as with K562 cells (Fig.  1 B and C) . HeLa cells exhibited no evidence of this mRNA. The abundance of hEpoR mRNA evaluated by comparison with that of coamplified 3-actin cDNA revealed roughly similar levels in HUVECs and K562 cells which were distinctly lower than those of OCIM1 cells. These studies were complemented by quantification of hEpoR mRNA (Fig. 2 with an internal standard constructed from an overlapping segment of the hEpoR target sequence (12) . The amount of cDNA/pg of mRNA of duplicate quantitative PCR experiments was 3.0 x 10-4 ng for HUVECs, 4.8 x 10-3 ng for OCIM1, and 2.3 x 10-4 ng for K562 cells.
To further exclude the possibility that the hEpoR mRNA detected was produced by small numbers of hematopoietic progenitors that remained undetected in our clonal cultures, we added to our standard HUVEC cultures (6) hematopoietic growth factors at concentrations similar to those ofour clonal cultures, changing the supplemented medium every 3 days. After 10 days, all cells were harvested and their mRNA was extracted and analyzed by PCR for the presence of a-and -globin mRNA, using reverse transcriptase (for conversion to cDNA) and primer pairs specific for each globin type (Fig.  3 ). PCR products corresponding to a-globin and ygiobin transcripts were found in OCIM1 cells but not in HUVECs or HeLa cells. These results provide further confirmation ofthe absence of erythroid precursors in our HUVEC cultures.
Immunostaining ofumbilical cord and placental vessels with antibody to vWF showed strong reactivity ofthe endothelium ofumbilical veins and ofplacental blood vessels having muscle walls ( Fig. 4 C and D) . Staining of septal and villous thin capillaries of placental tissue was weak and inconsistent. Similar results were obtained when umbilical cord and placenta tissue sections were reacted with mouse anti-hEpoR monoclonal antibody mh2er/16.5.1. This antibody binds to the soluble version of hEpoR on several receptor-positive cell lines and inhibits binding of Epo to its receptor (13) . The endothelium of umbilical veins (Fig. 4A ) and of placental septal blood vessels containing muscle wall (Fig. 4B ) showed strong EpoR positivity. Placental capillaries and other cells were negative (Fig. 4B ). Vascular endothelial cells are remarkably heterogeneous in terms of morphology, expression of molecular markers, and biological function (14) and many capillaries are vWF negative (x90.) (15) . Although the histochemical staining pattern ofanti-hEpoR seems similar to that of anti-vWF, we do not yet have detailed comparative studies in other tissues to know whether this congruence extends to other vascular areas.
Our previous studies have shown that HUVECs have many more EpoRs than OCIM1 cells or other erythroid cells; however, the quantity of hEpoR mRNA in HUVECs as shown in this study is less than that in OCIM1 cells. We have no experimental evidence to explain this discrepancy, but several explanations can be suggested. In erythroid cells, the mature EpoR has an exceedingly short half-life (45-60 min), in sharp contrast to other receptors-e.g., transferrin, insulin, and asialoglycoprotein receptors, which have half-lives from 7 to 20 hr. Less than 5% of the EpoRs are found on the cell surface (16, 17) . Migliaccio et al. (18) have proposed that it is the cellular environment in which the EpoR gene is expressed, and not simply its expression, that determines the erythroid-specific processing and function of EpoR.
The concept of strict erythroid or even hematopoietic specificity of EpoR is being challenged not only by our studies but also those ofMasuda et al. (19) , who have recently described the presence of EpoR in two rodent cell lines of neural origin. Ohneda et al. (20) also observed a dosedependent mitogenic response to Epo of murine fetal liver stromal cells and detected EpoR mRNA in those cells. They hypothesized a possible involvement of Epo in the development of the fetal hematopoietic microenvironment.
Although functional high-affinity EpoR is expressed mostly at the erythroid-colony-forming unit and proerythroblast level-i.e., in erythroid cells of very late maturation stage (1)-Heberlein et al. (21) observed low levels of EpoR gene transcripts in embryonal or multipotential cell lines. These primitive cells had 10-100 times less EpoR mRNA than more mature stages of erythroid precursors. In fact, the EpoR gene seems to be expressed at low levels before either hematopoietic or erythroid commitment has occurred (21, 22) , giving rise to speculation that EpoR in these early cells can transmit a proliferative signal either by itselfor in synergy with other cytokine receptors (21) .
Epo exerts primarily a mitogenic effect on early erythroid precursors and a mostly differentiating effect on later erythroid precursors (1) . Erythroid cells or cell lines which respond to exogenous Epo by proliferation only (or are unresponsive) often have a single class of low-affinity receptors (23) . Primitive erythroid progenitor cells (CD34+, CD71-) contain a truncated form of the receptor capable of transducing a mitogenic signal, whereas more mature erythroid cells (CD34-, CD71+) contain the full-length receptor (24) . The mitogenic effect of Epo on HUVECs seems similar to that on primitive stem cells. In HUVECs, we found an Epo-induced increase in cell number and [3H]thymidine incorporation (3) and a decrease in the phosphorylation of p34cdc2 (25) , all in association with a high number of low-affinity hEpoRs.
Endothelial cells coexpress antigens characteristic of hematopoietic cells of various lineages (26) and produce constitutively, or after induction, hematopoietic growth factors and cytokines (27) (28) (29) . Presently, they are the only human nonhematopoietic cells expressing the p55 chain of the interleukin 2 receptor (30) and, as shown by us, hEpoR. Of particular interest is their expression of markers of primitive hematopoietic cells, such as the CD34 antigen (31, 32) and GATA-2 protein (33) . GATA-1 is recognized as an erythroidspecific transcription factor, but GATA-2 is also expressed in more primitive progenitor cells, possibly signaling the onset of commitment of mesoderm to form hematopoietic tissue (34) .
The vascular system is the earliest to develop in embryos, to best serve the metabolic requirements of other tissues. Although the presence ofhEpoR in cultured endothelial cells cannot be a priori equated to in vivo situations, it does suggest that Epo controls early mitogenic pathways for the development of the embryonic vasculature. Schmitt et al. (22) have also suggested that an early action of Epo may be to stimulate the development and activation of embryonic endothelial cells to produce a varied array of hematopoietic growth factors and cytokines. In fact the first recognizable hematopoietic tissue, the blood islands ofthe yolk sac, are composed of only endothelial cells and blood cells (35, 36) . At this time, however, the in vivo role of endothelial hEpoR remains enigmatic.
